Business Context and Reporting Period
This Form 8-K was filed by Alphatec Holdings, Inc. on September 28, 2021. The report addresses Item 8.01 (Other Events) and discloses a business update regarding the Company's expected third-quarter 2021 revenue results, specifically highlighting the impact of the COVID-19 pandemic.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification of a press release (Exhibit 99.1) containing the business update rather than a detailed financial statement.
Material Changes
The Company reported a material change in its expected third-quarter 2021 revenue outlook due to the ongoing impact of the COVID-19 pandemic. No specific quantitative comparison to the prior period is provided in this filing text.
Guidance, Outlook, and Risks
Management issued forward-looking statements regarding revenue and growth outlook, planned product launches, regulatory submissions, and efforts to transform sales channels. The filing explicitly warns that actual results may differ materially from projections due to several risks, including:
- Uncertainty in developing new products or pipeline items.
- Challenges in executing the strategic operating plan.
- Potential failure to achieve surgeon adoption of products.
- Risks related to FDA or other regulatory clearances.
- Continuation of favorable third-party reimbursement.
- Competitive pressures and emerging technologies.
- Product liability exposure and litigation outcomes.
- Intellectual property claims.
- Ability to meet financial obligations.
- Continued economic impact of the COVID-19 pandemic.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific revenue guidance figures and the magnitude of the COVID-19 impact.
- Verify the Company's current cash position and ability to meet financial obligations given the revenue uncertainty.
- Monitor upcoming regulatory submissions and FDA clearance statuses for pipeline products.
- Assess the status of third-party reimbursement rates for the Company's product portfolio.
- Track surgeon adoption rates and feedback on new product introductions.